https://journals.eikipub.com/index.php/AIM-Medicine <p>The <strong>Annals of Innovation in Medicine (AIM)</strong> is a publication that provides a platform for researchers, physicians, and other medical professionals to share their findings, discoveries, and insights on various medical topics with a focus on innovation. It serves as a valuable resource for healthcare professionals who want to stay up-to-date with the latest developments and advancements in the field of medicine, particularly in areas related to new technologies, techniques, and processes.</p> <p><strong>ISSN <a href="https://portal.issn.org/resource/ISSN/2977-0335">2977-0335</a></strong></p> European Institute of knowledge and innovation (EIKI LTD) en-US Annals of Innovation in Medicine 2977-0335 https://journals.eikipub.com/index.php/AIM-Medicine/article/view/376 <p>Portal hypertensive patients candidate for Band ligation were administered Omeprazole tab (proton pump Inhibitor) in Al-Managel Hospital to assess post-ligation ulcer healing and Heartburn, dysphagia and odynophagia Symptoms following ligation. Forty-five patients were treated with Omeprazole tab 20 mg twice daily for one week immediately after the ligation session and rechecked in the next session (3-4) weeks later. Healing of post-banding ulcers occurs naturally without significant association with using Omeprazole, as examined by Qui Square and Fisher's exact test. Omeprazole is significantly associated&nbsp;with decreased heartburn and odynophagia symptoms as checked by an Independent Paired T-test. Adjunctive use of Omeprazole with Band ligation for Portal Hypertensive patients is recommended to improve post-ligation symptoms of heartburn and odynophagia.</p> Samar Musa Moawia El Balal Merghani Yousif Ibrahim Omer Copyright (c) 2025 Annals of Innovation in Medicine https://creativecommons.org/licenses/by/4.0 2025-01-15 2025-01-15 3 1 10.59652/aim.v3i1.376